Abstract Two years into the operation of the Unified Patent Court, Amgen v Sanofi/Regeneron is, alongside Edwards Lifesciences v Meril, the first decision on the merits from the Court of Appeal that tackles the inventive step and sufficiency requirements. This landmark decision might shape European patent litigation before the Unified Patent Court for years to come, particularly in the field of antibody drugs. We critically assess potential differences between the criteria applied by the European Patent Office, the Unified Patent Court and the Supreme Court of the United States.
Velasco et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: